Background
International multicenter phase III trial randomizing 1:1 patients with large B-cell lymphoma refractory to or relapsed ≤12mo after first-line therapy to axicabtagene ciloleucel (axi-cel) vs standard-of-care salvage chemoimmunotherapy followed by autologous transplant in responders. Bridging (except steroids) and crossover were not permitted. Median age 59yr (30% >65yo); 74% primary refractory; 79% stage III/IV; 16% double/triple-hit.
Interventions and follow up
Arm A: axi-cel after lymphodepletion with fludarabine 30 mg/m2 + cyclophosphamide 500 mg/m2 x3 days
Arm B: investigator-selected salvage chemoimmunotherapy, with autologous transplant in responders (CR/PR)
Primary endpoint: EFS (progression, new lymphoma therapy, death, or SD at day-150 assessment)
Secondary endpoints: OS, PFS, safety
mFollow up: 24.9mo
Arm B: investigator-selected salvage chemoimmunotherapy, with autologous transplant in responders (CR/PR)
Primary endpoint: EFS (progression, new lymphoma therapy, death, or SD at day-150 assessment)
Secondary endpoints: OS, PFS, safety
mFollow up: 24.9mo
Results
Treatment delivery: 94% received axi-cel; in SOC arm only 36% reached autologous transplant
mEFS: 8.3mo (axi-cel) vs 4.5mo (SOC); HR 0.40, 95% CI 0.31–0.51, P<.001
2yr EFS: 41% vs 16%
mPFS: 14.7mo vs 3.7mo
2yr PFS: 46% vs 27%
mOS: NR (axi-cel) vs 35.1mo (SOC)
2yr OS: 61% vs 52%
mEFS: 8.3mo (axi-cel) vs 4.5mo (SOC); HR 0.40, 95% CI 0.31–0.51, P<.001
2yr EFS: 41% vs 16%
mPFS: 14.7mo vs 3.7mo
2yr PFS: 46% vs 27%
mOS: NR (axi-cel) vs 35.1mo (SOC)
2yr OS: 61% vs 52%
Adverse events
Grade ≥3 overall: 91% (axi-cel) vs 83% (SOC); one treatment-related death in each arm
CRS (axi-cel): 92% any grade, 6% grade ≥3
ICANS/neurologic events (axi-cel): 60% any grade, 21% grade ≥3
CRS (axi-cel): 92% any grade, 6% grade ≥3
ICANS/neurologic events (axi-cel): 60% any grade, 21% grade ≥3
Conclusions
Axi-cel as second-line therapy significantly improved EFS over salvage chemoimmunotherapy plus autologous transplant in early-relapsing or primary-refractory large B-cell lymphoma, establishing CAR T-cell therapy as a new second-line standard. A subsequent OS update confirmed an overall survival benefit.
Key Limitations
No bridging chemotherapy allowed in the axi-cel arm, which may disadvantage rapidly progressing SOC patients differently. Many SOC patients never reached transplant, and a substantial fraction received CAR T off-protocol after progression, confounding OS interpretation.
Clinical Context
Supported FDA approval of axi-cel for second-line LBCL refractory to or relapsing ≤12mo after first-line therapy. ESMO and ASCO endorse second-line CAR T-cell therapy for primary-refractory or early-relapsing LBCL.
References